Cargando…
Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas
Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of lymphocyte homeostasis, resulting from mutations in the Fas apoptotic pathway. It is characterized by non-infectious and non-malignant chronic lymphoproliferation and an increased risk of lymphoid malignancy. The diagnosis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733459/ https://www.ncbi.nlm.nih.gov/pubmed/36523284 http://dx.doi.org/10.11604/pamj.2022.43.61.33009 |
_version_ | 1784846381157974016 |
---|---|
author | Youssif, Houda Ben Ailal, Fatima Benhsaien, Ibtihal Bakkouri, Jalila El Jeddane, Laila Maani, Khadija El Bousfiha, Ahmed Aziz |
author_facet | Youssif, Houda Ben Ailal, Fatima Benhsaien, Ibtihal Bakkouri, Jalila El Jeddane, Laila Maani, Khadija El Bousfiha, Ahmed Aziz |
author_sort | Youssif, Houda Ben |
collection | PubMed |
description | Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of lymphocyte homeostasis, resulting from mutations in the Fas apoptotic pathway. It is characterized by non-infectious and non-malignant chronic lymphoproliferation and an increased risk of lymphoid malignancy. The diagnosis of this condition usually combines chronic lymphadenopathy and/or splenomegaly exceeding 6 months, autoimmune cytopenias, with an elevated level of CD3+CD4-CD8- Tαβ lymphocytes, known as “double-negative” T cells. Differential diagnosis includes infections, autoimmune diseases or malignancies. Although clinical examination and laboratory tests are highly suggestive, this disease goes widely unrecognized. We here report, for the first time, the case of ALPS, a Moroccan patient, and aged 8 years, with recurrent fever, splenomegaly and adenopathies. Paraclinical examinations revealed chronic pancytopenia, higher than normal TαÎ(2) double negative lymphocytes, hypergammaglobulinemia, and elevated serum levels of soluble FAS ligand. The diagnosis of ALPS was made. First-line treatment included corticosteroids and immunoglobulins. Then the patient received mycophenolate followed by Sirolimus. This treatment resulted in better clinical and laboratory tests results. Our aim is to raise awareness of this rare condition, which may be under-diagnosed, among physicians. |
format | Online Article Text |
id | pubmed-9733459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-97334592022-12-14 Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas Youssif, Houda Ben Ailal, Fatima Benhsaien, Ibtihal Bakkouri, Jalila El Jeddane, Laila Maani, Khadija El Bousfiha, Ahmed Aziz Pan Afr Med J Case Report Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of lymphocyte homeostasis, resulting from mutations in the Fas apoptotic pathway. It is characterized by non-infectious and non-malignant chronic lymphoproliferation and an increased risk of lymphoid malignancy. The diagnosis of this condition usually combines chronic lymphadenopathy and/or splenomegaly exceeding 6 months, autoimmune cytopenias, with an elevated level of CD3+CD4-CD8- Tαβ lymphocytes, known as “double-negative” T cells. Differential diagnosis includes infections, autoimmune diseases or malignancies. Although clinical examination and laboratory tests are highly suggestive, this disease goes widely unrecognized. We here report, for the first time, the case of ALPS, a Moroccan patient, and aged 8 years, with recurrent fever, splenomegaly and adenopathies. Paraclinical examinations revealed chronic pancytopenia, higher than normal TαÎ(2) double negative lymphocytes, hypergammaglobulinemia, and elevated serum levels of soluble FAS ligand. The diagnosis of ALPS was made. First-line treatment included corticosteroids and immunoglobulins. Then the patient received mycophenolate followed by Sirolimus. This treatment resulted in better clinical and laboratory tests results. Our aim is to raise awareness of this rare condition, which may be under-diagnosed, among physicians. The African Field Epidemiology Network 2022-10-07 /pmc/articles/PMC9733459/ /pubmed/36523284 http://dx.doi.org/10.11604/pamj.2022.43.61.33009 Text en Copyright: Houda Ben Youssif et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Youssif, Houda Ben Ailal, Fatima Benhsaien, Ibtihal Bakkouri, Jalila El Jeddane, Laila Maani, Khadija El Bousfiha, Ahmed Aziz Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title | Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title_full | Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title_fullStr | Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title_full_unstemmed | Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title_short | Syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
title_sort | syndrome lymphoprolifératif avec autoimmunité: à propos d’un cas |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733459/ https://www.ncbi.nlm.nih.gov/pubmed/36523284 http://dx.doi.org/10.11604/pamj.2022.43.61.33009 |
work_keys_str_mv | AT youssifhoudaben syndromelymphoproliferatifavecautoimmuniteaproposduncas AT ailalfatima syndromelymphoproliferatifavecautoimmuniteaproposduncas AT benhsaienibtihal syndromelymphoproliferatifavecautoimmuniteaproposduncas AT bakkourijalilael syndromelymphoproliferatifavecautoimmuniteaproposduncas AT jeddanelaila syndromelymphoproliferatifavecautoimmuniteaproposduncas AT maanikhadijael syndromelymphoproliferatifavecautoimmuniteaproposduncas AT bousfihaahmedaziz syndromelymphoproliferatifavecautoimmuniteaproposduncas |